Compare Moderna, Inc. (MRNA) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Sibanye Stillwater Ltd — how do they compare? Moderna, Inc. trades at $136.55 (market cap $54.14B), while Sibanye Stillwater Ltd trades at $13.02 (market cap $9.31B). The key difference: Moderna, Inc. is far larger — about 5.8× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays a 6.17% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | SBSW | |
|---|---|---|
Market Cap | $54.14B | $9.31B |
Sector | Health | Basic Materials |
52-Week High | $174.38 | $21.12 |
52-Week Low | $22.36 | $8.00 |
Enterprise Value | $50.29B | $10.24B |
Dividend Yield | — | 6.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
SBSW trades at $12.90, up 0.86% with a bullish technical signal. The company shows strong operational momentum with 54% YoY revenue growth and 111% EBITDA growth in H1 2026. Valuation metrics appear attractive with P/E of 10.2 and P/S of 0.88. Analyst consensus is mixed with 43% buy ratings and $14.00 price target, while technical indicators show bullish moving averages and neutral oscillators.
The outlook suggests potential upside from current levels supported by strong H1 2026 results and disciplined capital allocation. Key risks include commodity price volatility and the company's recent history of net losses. The stock presents a turnaround opportunity with improving cash flow trends and operational efficiency gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
